GlassScriptPhysician profile
Ellen Szwed
NPI 1366604480
$772.29
in general payments reported to CMS, 2019-2025
18 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $24.84 · 2021: $86.31 · 2024: $27.49 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $142.64 | 2019-2021 | |
| Springworks Therapeutics, INC. | $121.15 | 2025 | Gomekli |
| Celgene Corporation | $74.27 | 2019 | |
| Pfizer INC. | $73.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.69 | 2019-2020 | |
| Puma Biotechnology, INC. | $41.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.64 | 2019 | |
| Eisai INC. | $32.99 | 2019 | |
| Tersera Therapeutics LLC | $31.40 | 2019 | |
| Myriad Genetic Laboratories, INC. | $27.49 | 2024 | Myrisk |
| Merck Sharp & Dohme LLC | $25.60 | 2019-2020 | |
| Janssen Biotech, INC. | $20.02 | 2019 | |
| Genentech USA, INC. | $17.44 | 2019 | |
| Kyowa Kirin, INC. | $15.93 | 2019 | |
| Clovis Oncology, INC. | $14.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.33 | 2019 | |
| Amgen INC. | $13.19 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Szwed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.